SELLAS Life Sciences Group Target of Unusually High Options Trading (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of unusually large options trading on Monday. Stock investors purchased 9,455 call options on the company. This is an increase of 146% compared to the typical volume of 3,838 call options.

SELLAS Life Sciences Group Price Performance

NASDAQ SLS opened at $1.49 on Wednesday. The stock has a market capitalization of $104.87 million, a P/E ratio of -2.16 and a beta of 2.41. The firm’s 50-day moving average is $1.06 and its two-hundred day moving average is $1.17. SELLAS Life Sciences Group has a 12 month low of $0.56 and a 12 month high of $1.84.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Hedge funds have recently made changes to their positions in the stock. Opus Capital Group LLC increased its holdings in SELLAS Life Sciences Group by 5.5% during the 4th quarter. Opus Capital Group LLC now owns 238,500 shares of the company’s stock worth $248,000 after purchasing an additional 12,400 shares during the period. Virtu Financial LLC raised its holdings in shares of SELLAS Life Sciences Group by 24.1% in the 3rd quarter. Virtu Financial LLC now owns 79,241 shares of the company’s stock valued at $99,000 after purchasing an additional 15,398 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of SELLAS Life Sciences Group during the 2nd quarter worth $39,000. State Street Corp grew its stake in shares of SELLAS Life Sciences Group by 30.2% during the third quarter. State Street Corp now owns 174,529 shares of the company’s stock worth $218,000 after purchasing an additional 40,500 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in SELLAS Life Sciences Group in the third quarter valued at $78,000. Hedge funds and other institutional investors own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.